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ABSTRACT
Background
The transfusion transmitted emerging infectious agents has become a
real threat to the transfusion safety. Human parvovirus B19 is one of the
common viral infection worldwide with a potential threat of transfusion
transmission through blood and its products particularly affecting the high risk
groups. Introduction of screening test for detecting Human parvovirus B19
antibodies for blood donors needs further evaluation for its potential risk and
cost effectiveness.
Aim
To find out the seroprevalence of Human parvovirus B19 among
voluntary blood donors in Chennai.
Materials and Methods
106 blood samples from voluntary blood donors were collected in one
year period from July 2015 to June 2016 and were subjected to IgM and IgG
serological tests using NovaLisa Human parvovirus B19 ELISA kits. Data
analysis was done using SPSS software and Chi-square test was used to find
statistical significance.
Results
Among 106 voluntary blood donors, 44.3% of the donors were positive
for anti-B19V IgG and none were positive for anti-B19V IgM. There was a
statistically significant difference (p=0.018) in IgG positivity among different
age group. Percentage of IgG B19V seropositivity gradually increases along
with increase in age of the donors. Statistically significant difference (p=0.001)
in IgG positivity in different socioeconomic groups affecting lower
socioeconomic group more than the middle and higher groups. There was a
statistically significant difference (p=0.019) in IgG positivity during different
months in a year. Among 47 donors positive for IgG B19V, one was positive
for HBsAg and two were positive for anti-HCV.
Conclusion
The seroprevalence of anti-B19V IgG in blood donors is 44.3%. All
donor samples in this study were seronegative for IgM. Further larger studies
are needed to confirm the possibility of transfusion transmission of Human
parvovirus B19, to estimate clinical impacts on recipients and to justify the
introduction of donor screening for Human parvovirus B19. Till then it is
imperative to screen blood components at least for high risk recipients.
Keywords
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INTRODUCTION
1INTRODUCTION
Blood transfusion is a lifesaving therapy in hospital practices for
patients. It is proven to be an invaluable human resource used for diverse kind
of medical and surgical conditions.1
Blood is a biologically active substance and for an effective blood
transfusion services, the blood and blood products provided should be safe as
possible and adequate to meet the patient requirements. Blood borne infections
are common and can be transmitted by transfusion of infected blood donated by
apparently healthy and asymptomatic blood donors.2 First step for safe blood
donation depends on, building a panel of  regular, voluntary, non-remunerated
blood donors.
According to WHO (World Health Organization), all blood donations
should be screened for infections prior to use. The goal of WHO is to obtain all
blood supplies from voluntary, non-remunerated donors by 2020.3
In India, it is essential to test every unit of blood collected for Hepatitis
B (HBsAg), Hepatitis C (Anti-HCV), Human Immunodeficiency Virus (HIV
1&2 antibodies), Syphilis (VDRL/RPR/TPHA) and Malaria (Thick and Thin
Blood Smear/ Antigen test).4 If a donor test positive to any of the five
infections, their blood is considered infectious and discarded.5 Moreover the
threat of emerging infectious agents worldwide continues to place demands on
the collection of blood to ensure safety.
2When a potential pathogen present in the donated blood gets transmitted
to a recipient via blood transfusion, it is called as Transfusion Transmitted
Infection (TTI). There are many infectious agents like bacteria, viruses,
protozoa and prions which can be transmitted through blood transfusion.6
Majority of the problems are due to the prevalence of asymptomatic carriers as
well as blood donations that are carried on during window period of infections.
The magnitude of the problem of transfusion transmitted infections varies from
country to country depending on the prevalence of that particular disease.7
Presently it has become essential to establish a risk control system against
emerging infectious diseases.8
The risk control system usually includes identifying emerging/re-
emerging infectious agents, any potential cause that could be
transmitted/transferred by blood transfusion, monitoring, assessing the severity,
evaluation, intervention (tests, donor history, pathogen reduction) and outcome
of the intervention.9
Ideally, blood for transfusion should be either tested for all pathogens
that are prevalent in a given population that can cause serious disease, or
treated to inactivate all such pathogens. In practice, neither is possible.10
Viral infections are of great importance in transfusions associated with
morbidity and mortality in patients. Viruses are easily transmitted by
transfusion because many donors are asymptomatic during the donation of
3blood.11 Most commonly proven viruses transmitted by transfusion include
HIV, HBV, HCV, HTLV, WNV, CMV and DENV. In addition to these
commonly transmitted viruses, Human parvovirus B19 adds to the list of
potentially transfusion transmissible infection as the virus can be demonstrated
in asymptomatic individuals.12
Human parvovirus B19 is one of the emerging causative agents of blood
borne infections worldwide.8
There is a large increase in the incidence of parvovirus infection as the
primary mode of transmission is mainly by respiratory route. The acute
infection is mild and self-limited, but it is clinically significant in those with
underlying haemolytic process, immunocompromised, transplant recipients and
pregnant women.12 The levels of viral DNA during acute infection can exceed
1012 IU/ml.13
Asymptomatic individuals with viremia as blood donors can represent a
risk to the safety of the blood supply, especially to high risk group such as
pregnant women, congenital or acquired haemolytic anemia,
immunodeficiency patients and transplant recipients.14 Hence there is an
increasing concern about the risk of parvovirus B19 transmission via blood
products posing a threat to the safety of blood supply.
4At present parvovirus B19 is not included in the mandatory donor
screening tests for transfusion transmitted diseases. According to FDA, the
recommended upper limit of viral load of parvovirus B19 for plasma
derivatives should not exceed 104 IU/ml.13 Since parvovirus B19 is emerging as
a common viral infection with a serious threat of getting transmitted via blood
transfusion, this cross sectional study was conducted to observe and analyse the
seroprevalence of Human parvovirus B19 among voluntary blood donors.
Although the risk of Transfusion transmitted human parvovirus B19
virus has been a concern, till date five proven cases have been identified
following blood component transfusion in high risk group recipients.15
Several studies done on European population between 1995-2014, on
the prevalence of parvovirus B19 in blood donor population reveal 6% to 79%
for IgG, 0.72% to 7.53% for IgM, 0.01 to 15.3% for IgG+IgM, 0% to 1.3% for
parvovirus B19 DNA.16 In India, among the blood donors, the seroprevalence
ranges from 27.96% to 39.9% for IgG, 7.3% for IgM and 2.40 % for
IgG+IgM.14
An estimate of the seroprevalence of Human parvovirus B19 among
voluntary blood donors may be of help to decide whether screening for
parvovirus B19 would eliminate transmission of infection to high risk groups.
Since, such studies are few in India, the present study was undertaken in an
attempt to address this aspect. Such information may be of great value to health
planners and policy makers.
AIM AND OBJECTIVES
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AIM
The aim of the study is to find the seroprevalence of Human parvovirus
B19 among voluntary blood donors in Chennai.
OBJECTIVES
1. To estimate the seroprevalence of Human parvovirus B19 among the
voluntary blood Donors in Chennai.
2. To detect anti-B19V IgM and IgG antibodies by ELISA.
3. To confirm anti-B19V IgM seropositive samples by PCR.
REVIEW OF LITERATURE
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Human Blood and its components is a lifesaving resource in hospital
practices. Safe and sufficient supply of blood and blood products for all
patients requiring transfusion is significant for every blood transfusion
service.16 The precious human resource in the form of voluntary blood donation
is the back bone of well organised Blood transfusion service.
Blood transfusion service is considered as one of the eight key life-
saving interventions in health care.18 Transfusion of blood and its products is a
specialised modality of patient treatment and management, saving millions of
lives worldwide each year and also reducing the morbidity.19
Voluntary non remunerated blood donors are the corner stone of a safe
adequate supply of blood and blood components.20 WHO (world health
organisation) recommends that all blood donations should be screened for
infection prior to use. The goal of WHO is to obtain all blood supplies from
voluntary unpaid donors by 2020 for all countries.3
The national blood policy in India depends mainly on voluntary blood
donors, as they are usually considered to be with low levels of transfusion-
transmitted infection. In India, it is mandatory to test every unit of blood
collected for Hepatitis B (HBsAg), Hepatitis C (Anti-HCV), Human
Immunodeficiency virus (HIV1&2antibodies), Syphilis (VDRL/RPR/TPHA)
and Malaria (Thick and Thin Blood Smear/antigen test).
7If a donor test positive to any of the five infections, their blood is
considered infectious and discarded.5 A spectrum of blood infectious agents is
transmitted by transfusion of infected blood donated by apparently healthy and
asymptomatic blood donors.6
Blood should be tested from each donation to identify donors and
donated components that might harbour infectious agents. This screening
process is critically important because many blood components (eg, red cells,
platelets, plasma, and cryoprecipitate) are administered intravenously to
recipients without pasteurization, sterilization, or other treatments to inactivate
infectious agents. Thus, infectious agents in a donor’s blood at the time of
donation that are not detected by the screening process can be transmitted
directly to recipients.10
For any infectious agent or infection to be transmitted by blood, usually
have the following characteristics: 21
? Duration of incubation period is long, before the appearance of clinical
signs.
? Stability in the blood stored at 40C or lower.
? Presence in the blood for long periods and in high titres.
? Asymptomatic phase in the blood donors.
8The various markers of infection usually appears at different times one
after another. For each Transfusion transmitted infection the window period
varies, ranging from few days to weeks and months, which in turn depends on
the type of the infectious agent, the screening marker and the screening
technology used. During the window period, the particular screening marker is
not detectable in a recently infected individual, but the individual may still be
infectious.22
The Nucleic acid (DNA or RNA), as a part of native infectious agent
itself, is the first detectable target, followed by antigen, and antibody as the
immune response develops. An effective and a well-organized blood screening
programme is essential for the provision of good quality and safe blood supply
to meet the transfusion needs of patients.22
Viral infections are of great importance in transfusions associated with
morbidity and mortality in patients. Viruses are easily transmitted by
transfusion because many donors are asymptomatic at the time of blood
donation. Most commonly transmitted viruses by transfusion include HIV,
HBV, HCV, HTLV, CMV, DENV and HUMAN PARVOVIRUS B19.
EMERGING INFECTIOUS DISEASE
In the year 2009, experts from AABB in United States reviewed about
the Emerging infectious disease agents. It includes recognition or spread of a
new agent, recognition of an infection or disease that has been in population
9but previously undetected or that a disease has an infectious origin and re-
appearance of a known infection after a decline in incidence.9 The rate of
emergence from 1940 to 2004 includes 5.3 new viruses discovered every year,
the expected rate of such emergence will continue beyond the year 2020.9
Human exposure can occur by a number of overlapping conditions,
many of which humans have clearly precipitated in ‘forcing’ a new agent by
mutation including the appearance of drug resistance strains, failure of existing
control measures, population movements and rapid transportation, Human
behavioural changes and intensive farming practices to name a few.23
The AABB identified around sixty eight EID agents of concern to blood
safety; each agent had enough evidence and potential for clinical disease to
warrant further consideration.23 Four categories were created based on priority
levels such as: red, orange, yellow and white.24 The red category was assigned
to those agents with low to high risk for blood safety; the agents with risk of
progression to a higher category in the future were classified as orange
category. And those agents that have absent to low evidence of risk to the
blood supply were classified as yellow category. White category includes
agents that the deems to pose no risk at this time.
Even though the emerging infectious agent that appears to pose biggest
risk to the blood supply are found in red and orange categories, the yellow
priority agents that includes Hepatitis A virus, HHV-8, HIV variants, Borrelia
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burgdorferi are gaining importance recently.24 In addition to these agents,
Human parvovirus B19 also adds to the list in the view that most cases are
asymptomatic and can cause transfusion transmitted infection in humans.25
HUMAN PARVOVIRUS B19
Human Parvovirus B19 (Latin word “Parvum” means “small”) is a
newly emerging  DNA virus, belongs to Erythroparvovirus genus, a member of
Parvoviridae family, Parvovirinae subfamily.26 The virus was discovered in
1975 by an Australian virologist, Yvonne Cossart, while working in London,
when screening donor sera for Hepatitis B virus, but found the B19 virus in the
sera, numbered 19 in row B, hence named it B19.16 B19 association with
disease was first identified in 1981, when it was linked to an aplastic crisis in a
patient with sickle cell disease.28 The virus was independently described in
Japan and France where it was called as Nakatani or aurillac antigen
respectively.
Human Parvovirus B19, the only known human pathogenic virus of the
Parvoviridae family.8 Parvovirus are the smallest of the known animal virus
having linear and single stranded DNA genomes. They are quite dense and
non-enveloped, the capsid proteins are arranged with icosahedral symmetry. It
is approximately 20-25 nm in diameter and can survive many inactivation
procedures, that are commonly used to protect the blood supply, and they can
remain fully viable at ambient temperature for months and even for years.
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The parvovirus B19 genome contains approximately 5600 nucleotides
and encodes three major proteins, two capsid proteins, VP1 and VP2 and a
non-structural protein, NS1.30 The capsid protein, VP2 is the major protein that
makes 95% of capsid structure, it can self-assemble on target cells and can bind
to the parvovirus B19 receptor, globoside (the blood group P antigen).The
capsid protein VP1 antigen contains the main neutralizing epitopes, and
essential for viral entry. The NS1 is a phosphoprotein, has important role in
activation of viral gene transcription, viral replication and encapsidation of the
viral genome within the virus. It is also cytotoxic and can cause cell cycle
arrest and induces apoptosis in infected cells.27
Figure 1: Structure of Human Parvovirus B1931
The parvovirus B19 genome is a well conserved genome with 10%
sequence variation between the isolates. Folding of the proteins creates alpha-
helical loops that appear on the surface of the assembled capsids, where the
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host immune system can recognize them as antigenic determinants. The unique
region of VP1 is external to the capsid and it has many linear epitopes
recognised by neutralising antibodies.
Figure 2:  Human parvovirus B19 icosahedral virion and genome
structure.16
PARVOVIRUS B19 GENOTYPE
There are three distinct genotypes (1, 2 and 3) and all studies in the
literature usually relate to type 1 genotype.30 The current serological assay can
detect all three genotypes.30 Genotype 1 is the most prevalent type and has a
worldwide distribution found in different time periods. Genotype 2 is seen in
patients from European countries, the United States and Brazil. Genotype 3 is
seen in tropical countries such as Brazil and Ghana. A new parvovirus
sequence PARV4 was discovered but it differs genetically from the parvovirus
B19 genotypes and probably a new genetic type of family Parvoviridae.32
Parvovirus cannot be cultured in any established cell line and they are
predominantly isolated from viremic human sera.26 Parvoviruses depend on
host and propagate in actively dividing cells.
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EPIDEMIOLOGY OF PARVOVIRUS B19
  Infection with Human parvovirus B19 is common and seen all over
world. The infectivity rates are almost similar in the United States, Europe and
Asia.33 It is mostly endemic, potentially emerging at any time during the year in
all seasons, although in temperate climates, outbreaks are commonly seen in
late winter and early summer. The infection are particularly apparent in
children, but it continues at a lower rate throughout adult life, by the time they
are elderly, most persons are seropositive. The seroprevalence of this virus
increases with age.34 Once infected, immunity generally persists for life, and it
is considered as a reliable marker of previous exposure.
PARVOVIRUS B19 TRANSMISSION
Human Parvovirus B19 virus is primarily transmitted by respiratory
droplets, and the virus can be detected in throat swabs during the initial period
for a week following infection. Initially replication occurs in nasopharyngeal
lymphoid tissue resulting in high titre viremia during which the viral load is at
concentrations of up to 1012 particles/ml of blood.32
Parvovirus B19 is also transmitted by blood and its products, mainly
through pooled factor VIII and factor IX concentrates.33 The small size of the
virus, absence of a lipid envelope and their genomic stability makes them
resistant to the heat and solvent detergent treatments and even escape removal
by filtration, traditionally used in pathogen inactivation technology in blood
products preparation.26
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The risk of vertical transmission varies between 30% to 50% following
exposure to infection in pregnant women.16 Transmission of infection may
occur in solid organ or haematopoietic transplantation and can lead to  serious
complications in such patients.16
PATHOPHYSIOLOGY
The only known natural host cell for Parvovirus B19 is the human
erythroid progenitor cells. The virus after entering blood initially replicates in
human erythroid progenitor cells (late erythroid cell precursors and burst-
forming erythroid progenitors of the bone marrow and blood, thereby inhibiting
erythropoiesis).35 Globoside, a neutral glycolipid that acts as a cellular receptor
accounts for the trophism in erythroid cells.33
Globoside is also known as erythrocyte P antigen.37 Individuals with rare
p phenotype blood group, whose erythrocytes lack P antigen are not susceptible
to infection and they have no serologic evidence to infection with Parvovirus
B19, their marrow erythroid progenitors proliferate normally in the presence of
high concentration of virus. The rare p phenotype frequency is 1 in 2, 00,000
and most commonly seen in Swartzentruber Amish population than in general
population.36 The presence of the P antigen alone is not sufficient for the virus
to gain entry into the human erythroid progenitor cells and it has been
suggested that some of the ?–integrins also acts as co-receptors for cellular
entry.34
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Figure 3: Schematic life cycle of B19.40
Once the virus binds the receptor, it is rapidly internalized by receptor
mediated endocytosis, mainly via clathrin-coated pits.26 Inside the host cells,
the viral DNA enters the nucleus. The 3' end of the viral DNA strand folds
back, forming a hairpin like bend that acts as a self-primer for viral DNA to
replicate. The virus is cytotoxic to the host cells. This, along with the tropism
for rapidly dividing erythrocyte precursors (particularly pronormoblasts and
normoblasts, wherein they replicate in high titers), leads to the suppression of
erythropoiesis seen during infection.
No reticulocytes are formed to replace aging or damaged erythrocytes as
they are cleared by the reticuloendothelial system. Although decreases in
hemoglobin levels of greater than 1 g/dL are rare in healthy individuals
infected with Parvovirus B19, decreases of 2-6 g/dL may be observed in
patients with haemolytic anemias. Occasionally, the virus can infect leukocytes
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(particularly neutrophils). Parvovirus B19 does not usually infect
megakaryocytes; however, in vitro, it is seen that parvovirus B19 proteins have
a cytotoxic effect on megakaryocytes. Although parvovirus B19 infection may
sometimes manifest with pancytopenia, it is not believed to contribute
significantly as an aetiology of true aplastic anemia.
Fetal myocardial cells also express P antigen and can be infected with
Parvovirus B19 and can lead to some of the direct myocardial effects seen
during fetal infection.
Both in vivo and in vitro studies, has shown that the pluripotent
erythrogenic stem cell is resistant to parvovirus B19 infection.26
PARVOVIRUS B19 STABILITY
Because of its small DNA genome and non-enveloped structure, B19 is
resistant to many inactivating procedures used to inactivate viruses. It is stable
in lipid solvents (ether, chloroform) but can be inactivated by formalin, beta-
propiolactone and oxidizing agents.30 The heat stability also varies depending
on the environment. B19 viruses can survive heat treatment at 480C for 30
minutes. In blood products parvovirus B19 retained infectivity after heating at
560C for 60 minutes. It is also virtually resistant to 600C heat for more than one
hour when suspended in 60% sucrose.30 Over recent year’s parvovirus B19 has
been used as a model virus for various viral inactivation procedures in
pathogen inactivation technology.23
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IMMUNE RESPONSE
Specific immunoglobulin IgM and IgG antibodies are produced
following infection with Parvovirus B19. In normal individuals who are
healthy the initial and predominant immune response is production of
antibodies. The parvovirus B19 immunological response is mainly directed
against two structural proteins, VP1 and VP2 proteins, which has both linear
and conformational epitopes.41 The VP1 and VP2 capsid proteins, coded from
the same reading frame, are identical except VP1 contains 227 additional
amino acids at the amino terminus.
Parvovirus B19 infection initially is characterised by a 5-day phase with
high viremia (titre about 1014 IU/ml parvovirus B19 DNA). This viremia is
neutralised with antibodies generated by the humoral immune system directed
against two structural proteins VP1 and VP2. IgA antibodies are also detectable
for a short period following the onset of clinical symptoms.42
The presence of specific IgM is consistent with the patient experiencing
an acute B19 infection. The presence of B19- specific IgG in the absence of
IgM is consistent with an infection in the remote past, with immunity to further
infection. This immunity is considered to be lifelong.43
A cellular immune response to B19 has been much harder to detect,
although it must be present to illicit the humoral response. Recent studies have
suggested that individuals mount a classic Th1 response to the virus, with
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capsid proteins presented to CD4 T cells through class II molecules.40 The cell-
mediated immune response occurs before the humoral immune response with
the proliferation of specific CD4+ T cells against the VP1 and VP2 antigens.
When the cellular immune response is activated, neopterin levels (6-D-erythro-
trihydroxipropilpterin) also increase in B19 infection. Neopterin is a direct
marker for monocyte activity and an indirect marker for macrophage activity.42
The pattern of clinical disease is strongly influenced by the hematologic
and immunologic status of the host. In the healthy host, B19 infection may
cause a self-limiting subclinical erythroid aplasia, followed by rash or
arthralgia mediated by the immune response. In patients suffering from
diminished production or increased destruction of erythrocytes, infection can
result in a dramatic decrease of haemoglobin, leading to aplastic crisis, whereas
immunocompromised individuals might fail to eradicate virus, thereby
generating a state of chronic anemia.
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Figure 4: Schematic depiction of T and B-cell response to parvovirus
B19infection34
CYTOPATHOLOGY
The effect of parvovirus B19 on progenitor cells of erythroid lineage in
bone marrow is characterised by the formation of giant pronormoblasts or
lantern cells. These are nothing but erythroid cells in early developmental stage
of diameter approximately around 24 to 30 µm, they have eosinophilic nuclear
inclusions bodies, cytoplasmic vacuolization, and occasionally, “dog ear,
projections. These abnormal cells are seen either in bone marrow or peripheral
blood. These cells are often absent in immunocompromised patients, patients
with Human immunodeficiency virus infection and other chronic infection.
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Hence their presence or absence is not helpful to make a diagnosis of B19
infection.40
CLINICAL ASPECTS
The spectrum of disease linked to parvovirus B19 infection range from
asymptomatic to serious and fatal conditions particularly in susceptible
population such as immunosuppression, decreased erythropoietic reserve, or
both.37
ASYMPTOMATIC INFECTION
The Parvovirus B19 presents mostly as a subclinical infection in adults
and children. In patients with haemolytic anemia the recently transfused
erythrocytes can mask the symptoms of the infection suggesting asymptomatic
seroconversion. It is mainly due to   transfused erythrocytes which has longer
life span than the erythrocytes of the host.40 In most of the cases the
presentation of symptoms is nonspecific which is similar to common flu  and in
many individuals the infection passes largely unnoticed.23
ERYTHEMA INFECTIOSUM
The most common manifestation of infection in children is fifth disease
or erythema infectiosum.25 It is also referred as “slapped cheek disease”. The
characteristic presentation is erythema over the face concentrated on the
cheeks, along with circumoral pallor which usually begins 2-3 weeks after
21
infection. Rashes also occur in the trunk and limbs. Prodromal symptoms
include fever, malaise, headache and nausea. The formation and deposition of
immune complexes in skin leads to these symptoms.33 This stage indicates
seroconversion, either IgM antibodies, or the presence of newly formed IgG
antibodies can be seen in serologic testing.
ARTHROPATHY
The most common manifestation of primary infection of parvovirus B19
in adults is non-erosive arthritis or arthralgia. It is commonly seen in females
than males.44 It is immunologically mediated due to circulating antibodies. The
joint symptoms often mimic rheumatoid arthritis, presenting as an acute
peripheral symmetric polyarthritis involving the metacarpophalangeal joints,
knee joint, ankle joints, without articular erosions.31
INFECTION IN PATIENTS WITH INCREASED RED CELL
TURNOVER
TRANSIENT APLASTIC CRISIS
In Patients with increased red cell destruction and increased demand for
the production of red cells, acute parvovirus B19 infection can cause an abrupt
cessation of red-cell production for 10 to 15 days and can lead to anemia.
Transient aplastic crisis is seen in patients with sickle cell anemia and
hereditary spherocytosis infected with Parvovirus B19. Although self -limited,
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an aplastic crisis can cause severe, occasionally fatal, anemia that precipitates
congestive heart failure, acute splenic sequestration and cerebrovascular
accident.40 The bone marrow during transient aplastic crisis is characterised by
an absence of maturing erythroid precursors and the presence of giant
pronormoblasts.
Conditions associated with decreased red cell production rendering
patients susceptible to B19-induced aplastic crisis includes iron deficiency
anemia, congenital dyserythropoietic anemia,1 alpha and beta thalassemia.
Transient aplastic crisis in patients with increased red cell destruction includes
hereditary spherocytosis, hereditary elliptocytosis, G6PD deficiency, pyruvate
kinase deficiency, sickle cell disease, malaria, chronic auto-immune haemolytic
anemia, cold and heat antibody mediated auto-immune haemolytic anemia,
paroxysmal nocturnal hemoglobinuria and even blood loss. Severe anemia with
B19 can also rarely affect healthy subjects with no underlying hematologic
disorder. Patients with transient aplastic crisis usually require transfusion
support for a satisfactory haemoglobin concentration.45
INFECTION IN IMMUNODEFICIENT HOST
CHRONIC PURE RED CELL APLASIA
In immunocompromised patients who are unable to produce neutralizing
antibody response due to a persistent BM insufficiency, B19 infection may
cause chronic anemia. Predisposing conditions include Nezelof’s syndrome,
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acute lymphatic leukemia (ALL), acute myeloid leukemia, chronic myeloid
leukemia, myelodysplastic syndrome, Burkitt’s lymphoma, lymphoblastic
lymphoma, myelodysplastic syndrome, astrocytoma, Wilms’stumor, HIV
infection, SCID, BM transplantation, organ transplantation, steroid and cancer
chemotherapy treatment. Patients usually have absent or low levels of specific
antibodies, with persistent or recurrent viremia. Clinical hallmarks include
fatigue and pallor, while immune-mediated symptoms (rash and arthralgia) are
generally absent. As patients fail to mount an antibody response, serological
diagnosis is not possible and detection of infection is usually achieved by PCR
assay.34
B19 INFECTION IN PREGNANCY
HYDROPS FETALIS
Parvovirus B19 infection in a pregnant woman, followed by
transplacental  transmission to the fetus, can lead to either miscarriage or
hydrops fetalis.46 The P blood group globoside , which acts as a receptor for
parvovirus B19, is present on cells of villous trophoblast of placental tissues in
varying amounts during pregnancy.32 Parvovirus B19 also infects the fetal liver,
the site of erythrocyte production during early development. The swollen
appearance in hydrops is due to severe anemia and myocarditis which leads to
congestive cardiac failure. Based on varies studies in United States47 and
United Kingdom48 the estimated risk of transplacental infection among
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pregnant women who are infected with parvovirus B19 during pregnancy is 30
percent, with a 5 to 9 percent risk of fetal loss and the  infection particularly
during the second trimester of pregnancy leads to greatest risk of
hydropsfetalis. Parvovirus B19 also accounts for 10 to 20 percent of all cases of
non-immune hydropsfetalis.
VIROLOGICAL DIAGNOSIS
VIRUS CULTURE
The virus is grown in culture with difficulty as there is no animal model
for culture. B19 virus can be cultured in erythroid progenitor cells from a
variety of sources such as human BM, fetal liver, umblical cord and peripheral
blood and in all culture system erythropoietin is required to maintain viral
replication. B19 virus can also be propagated in a few specialized cell lines:
two Megakaryoblastoid cell lines, MB-02 and UT-7/Epo and two human
Erythroid leukemic cell lines, JK-1 and KU812Ep6.40 The yield of virus from
all these cultures is poor, and they cannot be used as a source of antigen for
diagnostic tests.
DIAGNOSTIC CYTOPATHOLOGY
The characteristic cytopathological abnormality caused by parvovirus
B19is the formation of giant pronormoblasts (also referred to as lantern cells)
in the bone marrow, these are early erythroid cells with a diameter of 25 to 32
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µm in diameter,40 which is characterized by ground glass appearance of the
nucleus, perinuclear halo, immature chromatin and cytoplasmic vacuolization.
This cytopathological evaluation is particularly useful in the evaluation of
suspected hydrops fetalis41 but it is not sufficient for diagnostic purposes.32
IMMUNOHISTOCHEMISTRY
Immunohistochemistry can be used for the pathological examination of
different tissues materials from hydropicfetuses (thymus, liver, heart, placenta,
lungs, kidney). It enables visualisation of parvovirus B19VP1/VP2 within the
myocardium in hydropsfetalis. Since it is a time consuming method, it is not
routinely used as an diagnostic procedure.
RECEPTOR MEDIATED HEMMAGGLUTINATION ASSAY
Receptor mediated hemagglutination (RHA) assay was introduced by
Japanese Red Cross blood centres in 1998 and used as a screening test for
parvovirus B19 for all donated blood until 2007. It is a parvovirus B19 antigen
detection method in which the indicator RBCs agglutinate via parvovirus B19
particle binding to globosides on the RBC membrane at a critical pH. The
sensitivity of RHA is approximately 1010 IU/mL.48 This was replaced by
chemiluminescence enzyme immunoassay-based screening assay with a
sensitivity of approximately 107 IU/mL.
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SEROLOGICAL METHODS
The exact diagnosis of recent or past infection with B19 virus can be
detected by enzyme linked immunoassay to detect anti-B19 IgM and anti-IgG
or radioimmunoassay or immunofluorescence and for B19 DNA by using
PCR.40 The virus capsid proteins that are expressed in eukaryotic expression
system (the baculovirus expression system) is used in immunoassay system.
The co-expression of VP1 and VP2 in the eukaryotic expression system results
in empty capsids that are antigenically analogous to native B19 virions, these
co-capsids contain conformational epitopes that are essential for accurate
detection of infection. Recombinant VP1 and VP2 proteins, expressed in both
prokaryotic and eukaryotic systems, can be used to detect an immune response
against conformational or linear epitopes when non-denatured or denatured
antigens are used respectively.34
Figure 5:  Diagnostic markers of parvovirus B19infection in patient
serum40
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B19 IgM IMMUNODETECTION
The IgM antibodies usually appears 7-10 days post-infection and are
directed against linear and conformational epitopes of VP1 and VP2 antigens.
It usually persists approximately for 3-5 months.40 It indicates recently infected,
and thus potentially infectious individuals.23 Currently there is no international
standard preparation for B19 IgM.40
B19 IgG IMMUNODETECTION
Development of B19 IgG antibodies coincides with a decline in the IgM
response. These antibodies are protective, has life-long persistence and identify
previously infected rather than infectious individuals.23 The antibody response
wanes against linear epitopes on B19 capsid proteins, it persists against
conformational epitopes of both capsid proteins (VP1 and VP2).40
PCR DETECTION OF B19 DNA
The B19 PCR improves the sensitivity of detection of B19 infection.
The parvovirus B19 can even present rarely in the blood and bone marrow of
healthy subjects for long periods thus the qualitative PCR is not considered as a
valid diagnostic assay to confirm recent infection. The nucleic acid
amplification technology (NAT) assay for parvovirus B19 was standardised by
WHO. The 1st WHO international standard for parvovirus B19DNA for NAT
assays (code 99/800) was replaced by the 2nd WHO International Standard for
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parvovirus B19DNA for NAT assays (code 99/802) with a potency of 106 IU
mL-1 (or 105 IU per vial).49 This standardized PCR quantitative control is
applied for screening of plasma in minipools and other blood products, thereby
improving the safety of transfusion and the haematological treatment.
At present, there is no Food and Drug Administration (FDA) licensed
blood donor screening tests for Human Parvovirus B19.25 Moreover the
inability of transplant patients to produce sufficient anti-B19 Ig could present a
diagnostic dilemma resulting delay treatment in such patients who rely on
serological examination for the diagnosis Parvovirus B19.50 In such patients
PCR detection of Bl9 DNA is essential.
Various studies done in healthy blood donors in different countries had
shown variable seropositivity results for IgG and IgM parvovirus B19
antibodies.
A Seroprevalence study done by Manaresiet al51 in Bologna, Italy
among 446 healthy blood donors in Italy by IgG ELISA against capsid proteins
VP1 and VP2 showed 79.1% seropositivity. No significant difference was
found between men and women.
A Seroprevalence study of human parvovirus B19in 1633 healthy blood
donors done by Satish Kumar et al52 at Pune in India, showed the net
prevalence of IgM antibodies as 7.53% and prevalence of IgG antibodies as
27.96%. Dual positivity (IgG and IgM) was 2.40%.
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A Seroprevalence study done in healthy adult population by Rohrer et
al53 in German population among 6583 adults, showed anti-IgG positive in
72.1%, 66.9% in adolescents (18-19 years). Significant differences were
observed between females (73.3%) and males (70.9%).
A Seroprevalence study done in blood donors by Iheanachoet al44 in
Lagos, Nigeria among 150 voluntary blood donors showed anti-IgG positive in
66.0% and anti-IgM positive in 1.3%.
A Seroprevalence study by Kishore et al17 in 1000 North Indian
voluntary blood donors in India using in-house anti-B19 IgG ELISA showed
anti-IgG positive in 39.9%. Seroprevalence was higher in males than females
and it increased with increasing age. Socioeconomically, B19 IgG antibody
positivities were 61.8%, 61.1%, and 44.4% in low, medium, and high income
groups respectively.
Banwatet al1 reported the presence of anti-B19 antibodies among 88
blood donors in Kogi state, Nigeria. They showed 33(37.5%) out of 88 blood
donors were anti-IgG positive and 13 (14.8%) were anti-IgM positive. Males
had higher Seroprevalence compared to females for IgG.
Aldo Gaggeroet al54 studied the Seroprevalence of Human parvovirus
B19among 400 voluntary blood donors from Santiago, Chile. The overall
prevalence of IgG antibodies was 54.8%. No significant difference was found
between men and women (57.6% and 49.3%, respectively).
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DeokJa oh et al55 investigated the prevalence of parvovirus B19 DNA
and anti-parvovirus B19 antibodies in 928 randomly selected Korean
plasmapheresis donors. The rate of positive identification of anti-parvovirus
B19antibody (IgG only or IgG and IgM) among the donors was 60.1% (558 of
928 donors). The prevalence of parvovirus B19 DNA was 0.1%.
A seroprevalence of immunoglobulin G (IgG) to parvovirus B19 in 578
Saudi blood donors in Makkah, Saudi Arabia by Ayman K. johargy56 showed
76.3% positivity.
A Seroprevalence study by Mahmoodian-ShooshtariM et al57 in 1640
blood donors  in  Tehran, Iran showed, 8 (0.5%) subjects had IgM antibody
thereby being reported positive and 676 subjects (41.2%,) were positive for
anti-B19 IgG. B19 DNA was not found in any of the subjects (0%).
A Seorprevalence study by Al-Danani D.A et al58 among 100 healthy
blood donors in two cities, Aden in Yemen and Alexandria in Egypt showed,
46% and 26% respectively.
TRANSFUSION TRANSMITTED PARVOVIRUS B19
Of five previously reported cases of parvovirus B19 transmission by
single-donor blood components, three were by RBC transfusions and two was
by Platelet transfusion. The possible reasons for the paucity of the reports are
as follows:48 1) most of the transfusion recipients are immune to Parvovirus
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B19. 2) Parvovirus B19 infection usually does not cause a serious illness even
in non-immune adults affecting only patients in the immunocompromised
condition. 3) Passive immunization by the transfer of neutralizing anti-
parvovirus B19 antibodies mostly occurs with concurrent transfusion. 4) some
of the  risk factors that increase susceptibility  to severe parvovirus B19 disease
in recipients, and the signs and symptoms of TT-parvovirus B19 infection, are
not well recognized among clinicians.48
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Cases established as having TT-parvovirus B19 infection48
Case Patient profile
Before
Trans-
fusion
After
Transfusion
Symptoms and
laboratory
findings
Transfused
components
1 41,male
Hairycellleukemia
Afterchemotherapy
DNA (+)
IgM (+)
IgG(+)
RBCaplasia(3
months)
Reticulocytopenia
Viremia 0f 1×1012
copies/ml.
RBC (irradiated)
DNA(+) 1.8×105
IU/mL IgM(+)
IgG(+)
2 57, male
AML (M4)
After chemotherapy
DNA
(–)
IgM (–)
IgG (–)
DNA (+)
IgM (+)
IgG (+)
Pure RBC aplasia
(approx. 2
months)
PC (irradiated)
DNA (+)
9.7 ×108 IU/mL
2 × 1010 IU/bag
IgM (+) IgG (–)
3 35, female
Placenta previa
DNA
(–)
IgM (–)
IgG (–)
DNA (+)
IgM (+)
IgG (+)
Fever
Systemic eruption
(3 weeks
RBCs (irradiated)
DNA(+)
3.0 × 105 IU/mL
3 ×106 IU/bag
IgM (+) IgG (+)
4 59, male
Rectal cancer
DNA
(–)
IgM (–)
IgG (–)
DNA (+)
IgM (+)
IgG (+)
Sustained high
fever (5 days
RBCs (irradiated)
DNA(+)
5.1 × 103 IU/mL
5 × 104 IU/bag
IgM (+) IgG (+)
5 61, male
AML
After chemotherapy
DNA
(–)
DNA (+) High fever
Disseminated
erythema
Pure RBC aplasia
(7 weeks)
Reticulocytopenia
PC (irradiated)
DNA (+)
IgM (+) IgG (+)
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Viral concentrations as high as 1013 genome equivalents (geq) / mL are
often found in the blood of asymptomatic individuals during the early phase of
acute infection.48 There are reports of transfusion transmission by pooled
plasma-derived products, including factor 8 and other clotting factors despite
solvent/detergent (S/D) treatment, heat treatment, and other viral inactivation
methods in pathogen Inactivation. The IgG antibodies present in multiple
plasma donors are adequate enough to render the pooled plasma products non-
infectious, provided that no donor in the plasma pool has high-level viremia.
This provides the valid reason for excluding only those plasma donations for
further manufacturing that have viral titers exceeding approximately 106
IU/mL.47
PREVENTION OF TT-PARVOVIRUS B19
Currently no FDA guidelines or AABB standards exist in regard to
donor deferral period for Human Parvovirus B19.25
Prudent practice would be to defer any donor with signs and symptoms
of parvovirus B19 infection until they resolve. Currently there is no FDA-
licensed blood donor screening test for Parvovirus B19.25
Since the infectivity of the virus has been associated with a high
concentration of parvovirus B19 it is necessary to implement screening for
parvovirus B19 DNA by nucleic acid testing (NAT) to exclude high-titre
donations from manufacturing pools.
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WHO RECOMMENDATION FOR NAT ASSAY
The nucleic acid amplification technology (NAT) assay for parvovirus
B19was standardised by WHO. The 1st WHO international standard for
parvovirus B19 DNA for NAT assays (code 99/800) was replaced by the 2nd
WHO International Standard for parvovirus B19 DNA for NAT assays (code
99/802) with a potency of 106 IU mL-1 (or 105 IU per vial).49 This standardized
PCR quantitative control can be applied for screening of plasma minipools and
other blood products, thus improving the safety of transfusion and the
haematological therapy. The NAT assays used for screening of plasma
donations are recommended to target those viral genome regions that are
common to all three genotypes.49
STRATAGIES FOLLOWED IN DIFFERENT COUNTRIES
The universal screening of donated blood for parvovirus B19 by NAT is
currently carried out in Germany and Austria since 2000.16
In Poland the blood donors are tested for parvovirus B19 DNA since
2004.16
In United States, the FDA has proposed a limit of less than 104 IU/mL
for manufacturing pools for all plasma derivatives.13
In Netherlands, “B19 –virus safe” cellular blood products are defined as
those from a blood donor in which IgG antibodies against parvovirus B19 have
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been detected in two separate blood samples, one taken at least six months after
the other. The six month delay is to allow viral titre to fall, and for the presence
of high titre parvovirus B19 neutralising antibody. These cellular products are
used for administration to pregnant women, and B19-seronegative patients with
either haemolytic anemia or immunodeficiency.59
In Japan, the Japanese red cross blood centres has  introduced
parvovirus B19 antigen screening by chemiluminescent enzyme immunoassay
since 2008 for all donated blood with sensitivity of approximately 107 IU/mL.16
MATERIALS AND METHODS
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MATERIALS AND METHODS
STUDY METHOD
This Cross-sectional study was conducted over one year period from
July 2015- June 2016 in the Department of Transfusion Medicine, The Tamil
Nadu Dr.MGR Medical University, Guindy, Chennai. A total of 106 voluntary
blood donors were selected.
The study was approved by the ethical committee of The Tamil Nadu
Dr. MGR Medical University, Chennai. The donors were classified as upper,
middle and lower socioeconomic status based on Kuppusamy classification.60
SAMPLE COLLECTION
Five ml of blood was collected directly from voluntary blood donors in a
sterile plain test tube and allowed to clot; serum was separated and stored at
-20oC for ELISA and PCR tests.
INCLUSION CRITERIA
? Those voluntary blood donors who fulfil the criteria as per DGHS
guidelines.
? Those blood donors who are willing to participate in the study.
37
EXCLUSION CRITERIA
? Those voluntary blood donors who do not fulfil the criteria as per the
DGHS guidelines.
? Those blood donors who are not willing to participate in the study
ESTIMATED SAMPLE SIZE
? n= Z?2pq/d
2
? p=Prevalence=28
? q=1-p=72
? d=allowable error (10)
       n= (1.96)
2
x28x72
                         92
? Refusals and drop outs-10% (10)
? Minimum required sample size=106
STUDY PERIOD
The total sample size was split month wise from July 2015 to June 2016.
STATISTICAL ANALYSIS
? Data analysis was done using SPSS software
? Demographic details were given in descriptive statistics
? Quantitative data was given in summary statistics
? P<0.05 was considered significant
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METHOD OF SCREENING
The samples that were frozen earlier were thawed and used. Sera were
tested for Human Parvovirus B19, IgG and IgM by the enzyme-linked
immunosorbent assay (ELISA) test. Since there are no FDA (Food and Drug
Administration) licensed blood donor screening tests available worldwide,25
commercial diagnostic recombinant NovaTec Parvovirus B19 kit to detect IgG
and commercial diagnostic recombinant NovaTec Parvovirus B19 kit to detect
IgM  have been used in our study (Figures 6,8). This is based upon the use of
micro titer strip wells precoated with parvovirus B19 antigens (conformational
epitopes of VP-2 and linear epitopes of specific part of VP-1)64 to bind
corresponding antibodies of the specimen. All steps were done according to the
manufacturer's instructions. Reading was taken at 450 nm wavelength using an
ELISA microwell plate reader.
ASSAY PROCEDURE FOR IgG
1. All reagents were brought to the room temperature (20-250C) before
starting the test.
2. All reagents were mixed gently prior to use without inducing foaming.
3. A clean, disposable tip should be used for dispensing each control and
sample.
4. Dispense 100µl controls and diluted samples into their respective wells.
Leave A1 for substrate blank and cover wells with foil.
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Figure 6: Human Parvovirus B19 IgG ELISA Kit
5. Incubate for 1 hour at 370C.
6. After incubation, wash each well three times with 300µl of washing
solution.
7. Dispense 100µl parvovirus B19 anti-IgG conjugate into all wells except
for the blank well.
8. Incubate for 30 min at room temperature.
9. After incubation, wash each well three times with 300µl of washing
solution.
10. Dispense 100µl TMB Substrate Solution into all wells and incubate for
exactly 15 min at room temperature in the dark.
12. Dispense 100µl Stop Solution into all wells in the same order.
13. The optical density (OD) in each well was measured at 450 nm with
micro plate reader.
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MICROPLATE (IgG)
1 2 3 4 5 6 7 8 9 10 11 12
A BL
B NC
C PC
D CC
E CC
F S1
G S2
H S3
BL-Blank, NC-Negative Control, PC-Positive Control, CC-Cut-off Control,
S-Sample
Figure 7: Parvovirus B19 IgG ELISA plate
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Interpretation of results
Samples are considered POSITIVE if the absorbance value >10% of cut-
off value.
Samples are considered NEGATIVE if the absorbance value <10% of
cut-off value.
Samples with an absorbance value of 10% above or below the cut-off
value are considered in GREY ZONE.
It is recommended to repeat the test again 2-4 weeks later with a fresh
sample. If the second test are again in grey zone the sample is considered
NEGATIVE.
Results in Nova Tec Units
Cut-off 10       NTU
Grey zone 9-11    NTU
Negative < 9       NTU
Positive > 11     NTU
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CALCULATION OF RESULTS
Calculation of Nova Tec Units (NTU)
  Patient (mean) absorbance value × 10
NTU= ---------------------------------------------------
                                 Cut-off
Cut-off is the mean absorbance value of the Cut-off control
determination.
ASSAY PROCEDURE FOR IgM
1. All reagents were brought to the room temperature (20-250C) before
starting the test.
2. All reagents were mixed gently prior to use without inducing foaming.
3. A clean, disposable tip should be used for dispensing each control and
sample.
4. Dispense 100µl controls and diluted samples into their respective wells.
Leave A1 for substrate blank and cover wells with foil.
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Figure 8: Human Parvovirus B19 IgM ELISA kit
5. Incubate for 1 hour at 370C.
6. After incubation, wash each well three times with 300µl of washing
solution.
7. Dispense 100µl parvovirus B19 anti-IgG Conjugate into all wells except
for the blank well.
8. Incubate for 30 min at room temperature.
9. After incubation, wash each well three times with 300µl of washing
solution.
10. Dispense 100µl TMB substrate solution into all wells and Incubate for
exactly 15 min at room temperature in the dark.
11. Dispense 100µl stop solution into all wells in the same order.
12. The optical density (OD) in each well was measured at 450 nm with
micro plate reader.
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MICROPLATE (IgM)
  1 2 3 4 5 6 7 8 9 10 11 12
A BL
B NC
C PC
D CC
E CC
F S1
G S2
H S3
BL-Blank, NC-Negative Control, PC-Positive Control, CC-Cut-off Control,
S-Sample
Figure 9: Parvovirus B19 IgM ELISA plate
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Interpretation of results
Samples are considered POSITIVE if the absorbance value >10% of cut-
off value.
Samples are considered NEGATIVE if the absorbance value <10% of
cut-off value.
Samples with an absorbance value of 10% above or below the cut-off
value are considered in GREY ZONE.
It is recommended to repeat the test again 2-4 weeks later with a fresh
sample. If the second test are again in grey zone, the sample is considered
NEGATIVE.
Results in Nova Tec Units
Cut-off 10       NTU
Grey zone 9-11    NTU
Negative <9       NTU
Positive >11     NTU
CALCULATION OF RESULTS
Calculation of Nova Tec Units (NTU)
Patient (mean) absorbance value × 10
NTU= ---------------------------------------------------
                                      Cut-off
Cut-off is the mean absorbance value of the Cut-off control
determination.
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Polymerase chain reaction (PCR)
The polymerase chain reaction (PCR) is a technique used in molecular
biology to amplify a single copy or a few copies of a piece of DNA across
several orders of magnitude, generating thousands to millions of copies of a
particular DNA sequence.63
PCR amplifies a specific region of a DNA strand (the DNA target).
Most PCR methods typically amplify DNA fragments between 0.1 and 10 kilo
base pairs, although some techniques allow for amplification of fragments up to
40 kilo base pairs in size. The amount of amplified product is determined by
the available substrates in the reaction, which become limiting as the reaction
progress.
As PCR progresses, the DNA generated is itself used as a template for
replication, setting in motion a chain of reaction in which the DNA template is
exponentially amplified. The method relies on heating and cooling (thermal
cycling), consisting of cycles of heating and cooling of the reaction for DNA
denaturation of the double helix (melting) and enzymatic replication of the
DNA.
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Figure 10: PCR Procedure62
1. Select a PCR kit, which should include two primers, Taq DNA
Polymerase, deoxynucleotide triphosphates, Buffer solution.
2.  Obtain all necessary materials, equipment and instruments (kits should
include a detailed list of necessary items).
3.  A reaction mix is prepared, which includes dNTPs, primers, template
DNA, necessary enzymes and a buffer solution.
4. Add the mix to a PCR tube for each reaction. Then add the template
DNA.
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5. Place PCR tubes in the thermal cycler to begin cycling.
6. The first step is denaturation which causes DNA melting, yielding single
stranded DNA molecules.
7. The second step is annealing which allows annealing of primers to the
single stranded DNA.
8. The third step is elongation during which the DNA polymerase
synthesize New DNA strand complementary to the DNA template
strand.
9. The process of denaturation, annealing, and elongation consists of one
cycle.
10.  Agarose gel electrophoresis is employed for separation of PCR
products.
INFORMED CONSENT
All the study details will be explained to the donors in vernacular
language and consent will be obtained.
ETHICAL COMMITTEE CLEARANCE
Ethical clearance was obtained from the Institutional ethical committee
of The Tamil Nadu Dr. M.G.R Medical University, Chennai. (Copy enclosed).
RESULTS
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RESULTS
TABLE 1
Gender Distribution of the Study Group
Sex Number of donors Percentage %
Male 96 90.6
Female 10 9.4
Total 106 100.0
                                       Figure 11: Gender distribution
Demographic analysis showed, of the 106 donors, 96 (90.6%) were
males and 10 (9.4%) were females. (Table 1; Figure 11).
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TABLE 2
Age Distribution of the Study Group
Age group In years Number of Donors Percentage %
18-20 28 26.4
21-30 49 46.2
31-40 21 19.8
41-50 7 6.6
>50 1 1.0
Total 106 100.0
                                    Figure 12: Age Distribution
Age distribution among the blood donors were 26.4% in 18-20 years,
46.2% in 21-30 years, 19.8% in 31-40 years, 6.6% in 41-50 years, 1.0% in >50
Years. (Table 2; Figure 12).
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15.1%
48.1%
32.1%
4.7%
Donor Occupation
Professionals
Students
Clerical jobs
Coolie
TABLE 3
Distribution on the basis of occupation
Occupation Number of donors Percentage %
Professionals 16 15.1
Students 51 48.1
Clerical jobs 34 32.1
Coolie 5 4.7
Total 106 100
                                    Figure 13: Donor Occupation
Percentage distribution of blood donors on the basis of Occupation were
15.1 % of Professionals, 48.1% of students, 32.1% of Clericals, 4.7% of
Coolie. (Table 3; Figure 13).
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TABLE 4
Distribution on the basis of socioeconomic status
Socioeconomic status Number of donors Percentage %
Upper 17 16.0%
Middle 59 55.7%
Lower 30 28.3%
TOTAL 106 100.0%
Figure 14: Socioeconomic status
Most of our donors belong to middle socioeconomic status (55.7%)
followed by low (28.3%) and high (16%). (Table 4; Figure 14).
16%
55.70%
28.30%
Socioeconomic status
Upper
Middle
Lower
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                 Zonal Distribution of Voluntary Blood Donors
                                   Figure 15: Zonal distribution
Zonal distribution of donors were on the basis of their residence in and
around Chennai. Those within the city were divided further in to 15 zones. 104
donors were from 15 zones within Chennai city and 2 were from outside the
city limits.
According to zones in the city there were 3.8% in zone 1, 3.8% in zone
2, 0.9% in zone 3, 1.9% in zone 4, 0.9% in zone 5, 12.3% in zone 6, 15.1% in
zone 7, 7.5% in zone 8, 3.8% in zone 9, 12.3% in zone 10, 2.8% in zone 11,
15.1% in zone 12, 13.2% in zone 13, 4.7% in zone 15. The remaining 1.9%
were from outside the limits of Chennai city. (Figure 15).
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TABLE 5
Distribution of Blood Group
Blood Group Number of Donors Percentage %
A 24 22.6
B 37 34.9
O 36 34.0
AB 9 8.5
Total 106 100.0
Figure 16: Blood group distribution
Blood group distributions among the blood donors were 22.6% of ‘A’
group, 34.9% of ‘B’ group, 34.0% of ‘O’ group, 8.5% of ‘AB’ group.  (Table
5; Figure 16).
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TABLE 6
Distribution of Rh Type
Rh Type Number of Donors Percentage %
Positive 101 95.3
Negative 5 4.7
Total 106 100.0
                                         Figure 17: Rh Distribution
Rh distribution among donors were 95.3% of Rh D positive group, 4.7%
of Rh negative group. (Table 6; Figure 17).
95.3
4.7
Rh Distribution
Positive
Negative
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TABLE 7
Transfusion Transmitted Infection Status
TTI status Number of donors Percentage %
Reactive 3 2.8
Non-Reactive 103 97.2
Total 106 100
                                            Figure 18: TTI Status
Among 106 voluntary blood donors, three were found to be reactive, of
which one was found to be reactive for Hepatitis B Surface Antigen (HBsAg)
and two were found to be reactive for Hepatitis C Virus. (Table 7; Figure 18).
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TABLE 8
Month wise Sample Distribution
Month No. of Samples
July 2015 6
August 5
September 7
October 4
November 5
December 5
January 2016 11
February 13
March 12
April 14
May 13
June 11
                           Figure 19: Month wise Sample Distribution
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TABLE 9
Parvovirus B19 screening by Elisa
PARVOVIRUS B19 Positive Negative
IgM 0 106
IgG 47 59
             Figure 20: Human parvovirus B19 screening by ELISA
Human parvovirus B19 IgG antibody screening by ELISA showed that
59 were negative and 47 were positive, giving an overall parvovirus B19
prevalence rate of 44.3%. None of the 106 blood donors were reactive for
parvovirus B19 IgM antibodies by ELISA test. (Table 9; Figure 20).
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TABLE 10
Age Distribution of IgG seropositive
Age group In years
IgG seropositive donors
(Total donors)
Percentage %
18-20 5 (28) 17.8%
21-30 25(49) 51.0%
31-40 12(21) 57.1%
41-50 4(7) 57.1%
>50 1(1) 100%
TOTAL 47(106) 44.3%
                                                                                                                P=0.018
Figure 21: Age Distribution of IgG seropositives
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TABLE 11
Gender Distribution of IgG Seroprevalence
Sex
IgG seropositive donors
(Total donors)
Percentage %
Male 45(96) 46.9%
Female 2(10) 20.0%
TOTAL 47(106) 44.3%
                                                                                                                    P>0.05
                        Figure 22: Gender Distribution of IgG seropositives
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TABLE 12
IgG seropositive on the basis of socioeconomic status
Socioeconomic
status
IgG seropositive
donors (Total donors) Percentage %
High 5(17) 29.4%
Middle 20(59) 33.9%
Lower 22(30) 73.3%
TOTAL 47(106) 44.3%
                                                                                                                 P=0.001
Figure 23: IgG seropositives on the basis of socioeconomic status
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TABLE 13
Blood Group Distribution of IgG seropositives
Blood Group
IgG seropositive donors
(Total donors)
Percentage %
A 8(24) 33.3%
B 18(37) 48.6%
O 19(36) 52.8%
AB 2(9) 22.2%
TOTAL 47(106) 44.3%
P>0.05
             Figure 24: Blood Group Distribution of IgG seropositives
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TABLE 14
Rh Type Distribution of IgG seropositives
Rh Type IgG seropositivedonors (Total donors) Percentage %
Positive 45(101) 44.6%
Negative 2(5) 40.0%
Total 47(106) 44.3%
P>0.05
Figure 25: Rh Type Distribution of IgG seropositives
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TABLE 15
Zonal Distribution of IgG seropositives
Chennai Zones IgG seropositivedonors (Total donors) Percentage %
1 2(4) 50.0%
2 2(4) 50.0%
3 1(1) 100.0%
4 1(2) 50.0%
5 0(1) 0%
6 6(13) 46.2%
7 10(16) 62.5%
8 4(8) 50.0%
9 3(4) 75.0%
10 6(13) 46.2%
11 1(3) 33.3%
12 2(16) 12.5%
13 6(13) 42.9%
14 0(1) 0%
15 2(5) 40.0%
Outside 1(2) 50.0%
P>0.05
Figure 26: Zonal Distribution of IgG seropositives
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TABLE 16
Month wise Distribution of IgG Seropositive
Month IgGseropositives Donors
(Total Donors)
Percentage %
July 2015 2(6) 33.3%
August 4(5) 80.0%
September 3(7) 42.9%
October 3(4) 75.0%
November 1(5) 20.0%
December 2(5) 40.0%
January 2016 8(11) 72.7%
February 9(13) 69.2%
March 6(12) 50.0%
April 5(14) 35.7%
May 4(13) 30.8%
June 0(11) 0%
P=0.019
Figure 27: Month wise Distribution of IgG seropositives
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Comparison of IgG, IgM seroprevalence of Human Parvovirus B19 in various studies
Parameters Presentstudy
Satish
Kumar et
al52
Kishore
et al17
Manaresi
et al51
Rohrer et
al45
Iheanac
ho et al44
Banwat et
al1
Aldo
Gagger
o et al54
Ayman K.
johargy56
DeokJa
oh et al55
Mahmoodia
n-
Shooshtari
M
et al57
Al-
Danani
D.A,58
Hadia
Ahmed
Abou-
Donia
et al58
Gini GC. Van
Rijickevorsel
et al66
Place of study   Chennai Mumbai,India
Luckno
w, India
Bologna,
Italy Germany
Lagos,
Nigeria
Kogistate,
Nigeria
Santiag
o, Chile
Makkah,
Saudi
Arabia
Korea Tehran,Iran
Aden,
Yemen
Alexandri
a, Egypt Amsterdam
,Netherlands
Elisa Kit used Novalisa(IgG &IgM)
Serion
classic IgG
Novalisa
IgM
In-
house
Elisa
Medac
IgG
recomWel
l Elisa IBL Elisa
Demeditec
Diagnostic,
Germany
Focus
Diagno
stics
USA
Novalisa recomWell Elisa IBL Elisa IBL Elisa IBL Elisa Novalisa
Viral antigens coated
Recombina
nt antigens
VP1&VP2
Recombina
nt VP2/
Recombina
nt antigens
VP1&VP2
Purified
VP1/VP
2
capsid
proteins
VP1+VP2/
VP2 alone VP1+VP2
Parvovir
us B19
antigens
Parvovirus
B19
antigens
VP1
Recombina
nt antigens
 VP1&VP2
VP1+VP
2
Parvovirus
B19
antigens
Parvovir
us B19
antigens
Parvoviru
s B19
antigens
Recombinant
antigens
VP1&VP2
No of donors 106 1633 1000 446 6583 150 88 400 578 928 1640 100 100 1323
IgM seropositivity 0 % 7.53% - - - 1.3% 14.8% - - - 0.5% 26% 26% -
IgG seropositivity 44.3% 27.96% 39.9% 79.1% 72.1% 66.0% 37.5% 54.8% 76.3% 60.1% 41.2% 46% 26% 62.3%
Sex
Male 46.9% 28.4% 40.6% 78.2% 70.9% 65.3% 38.6% 57.6% 76.3% - - 46% 26% 60.7%
Female 20.0% 9.0% 27.3% 80.0% 73.3% 83.3% 20.0% 49.3% - - - - - 63.7%
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67
Age 18-20
21-30
31-40
41-50
>50
26.4%
46.2%
19.8%
6.6%
0.9%
-
40.3%
37.1%
44.5%
50%
77.0%
88.5%
66.9%
70.0%
70.0%
72.6%
79.1%
-
0%
46.7%
38.7%
0%
0%
-
68.0%
78.7%
69.8%
82.4%
82.6%
50.0%
56.9%
64.9%
64.4%
77.1%
-
31%
13%
2%
17%
4%
5%
64.8%
64.0%
61.4%
61.8%
Occupat
ion
Professiona
l
Student
Clerical
Coolie
31.3
27.5
70.6
80.0
- - - -
- - - - - - - - -
Socio-
econom
ic status
Upp
Mid
Low
29.4
33.9
73.3
-
44.4
61.1
61.8
-
71.3
71.8
74.3
- - - - - - - -
-
Blood
Group
A
B
AB
O
33.3
48.6
22.2
52.8
- - - - - - - - - - - - -
Rh
Type
Pos
Neg
44.6
40.0
- - - - - - - - - - - - -
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DISCUSSION
IgG Seroprevalence of B19V
In the present study, by testing serum of the 106 voluntary blood donors
against VP1 linear and VP2 conformational recombinant B19V antigens
(NovaLisa In-vitro Diagnostic Kit) revealed the seroprevalence rate 44.3%.
Since there is no FDA licensed blood donor screening test for B19V exists,25
the study was performed by using NovaLisa in-vitro Diagnostic kit.
Kishore et al,17 Lucknow, India screened 1000 voluntary blood donor
samples with in-house ELISA for  IgG (purified VP1 and VP2 capsid proteins)
revealed 39.9% of seroprevalence for B19V. This is slightly lower than our
study.
Satish Kumar et al,52 in their study in Mumbai, among 540 donors by
using  recombinant VP2 antigen (serion classic ELISA) showed 27.96%
seroprevalence for B19V. The lower prevalence rate could be because of using
only VP2 as the screening antigen in comparison to our study.
Similar studies using same antigens among 578 voluntary blood donors
by Ayman K.johargy56 in Saudi Arabia showed 76.3% seropositivity for B19V
infection. The increase in prevalence rate among voluntary blood donors of
different age group from 18 to 60 years could be explained by gradual increase
in seroprevalence of B19V among general population in accordance with
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increase in age in other studies.55,66 In our study also we observed similar
increase in prevalence rate for B19V parallel to increase in age of the donors.
Gini GC. Van Rijickvver sel et al,66 in their study in Amsterdam,
Netherlands among general adult population (n= 1323) using similar antigens
as that of our study revealed 62.3% prevalence rate for B19V.  The study
population included participants from Dutch, Morocco and Turkey who
showed prevalence rate of 59%, 61.1% and 67.2% respectively. The higher
prevalence rate could be due to the study being carried in general population
inclusive of participants from different ethnic origin.
DeokJa oh et al,60 in their study among 928 plasmapheresis donors in
Korea by using VP1 linear and VP2 Conformational antigens (recomWell
Elisa) revealed 60.1% of seroprevalence for B19V.  This study also reiterates
parallel increase in B19Vseroprevalence rate along with increasing age of the
donors.
The seroprevalence rate among other studies conducted in Lagos
Nigeria,44 Tehran Iran,57 Aden Yemen and Alexandria Egypt58 among
voluntary blood donors by using recombinant antigens (IBL Elisa, Germany)
revealed 66%, 41.2%, 46% and 26% respectively. Two of these studies
revealed almost same prevalence rate among voluntary blood donors in our
study.
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The study by Aldo Gaggero et al,54 in Santiago Chile among 400 blood
donors by using VP1 inactivated antigen (Focus Diagnostics USA) showed
54.8% of seroprevalence for B19V, which is almost similar to our study.
In our study out of 50 donor samples collected during the months of
January, February, March and April showed IgG B19V seropositivity in 28
(56%) samples. The prevalence rate is relatively higher during late winter and
spring seasons in our study, which is similar to the study done by Kishore et
al17 among 1000 voluntary blood donors in India and Cohen BJ et al84 study
done among 2000 participants from general population in England and Wales
(temperate climate region).
IgM Seroprevalence of B19V
In our study, none of the donors out of 106 at different age groups were
positive for anti-B19 IgM antibody, indicating the absence of primary
infection. However, the study by Satish Kumar et al52 reported 7.53% of anti-
B19 IgM antibody seropositivity among blood donors (n=1093) in Mumbai,
India. Banwat et al1 reported 14.8% anti-B19 IgM antibody among blood
donors (n=88) in Kogistate, Nigeria. These results reflect that the donors were
with recent infection. Mahmoodian-Shooshtari et al57 reported 0.5% anti-B19
IgM antibody seropositivity among blood donors (n=1640) in Tehran, Iran.
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Correlation of the results of IgG, IgM and PCR in our study
The 44.3% of the donors in our study were found to be positive for IgG
against VP1 linear and VP2 conformational antigens and none of them were
IgM positive. This could probably be due to the development of immunity to
the earlier infection.
Neal S. Young and Kevin E. Brown33 in their review article on
mechanism of disease in Parvovirus B19 has mentioned that antibody
production is correlated with the disappearance of virus from the blood and IgG
antibodies appear to confer lasting protection against re-infection. They have
also mentioned that antibodies to the unique amino-terminal region of VP1 are
important for clearance of the virus.
Saikava et al86 in their study on neutralizing linear epitopes of
parvovirus B19 cluster in the VP1 unique and VP1-VP2 junction regions have
also revealed that the antibodies against linear epitopes confer efficient
immunity compared to antibodies against VP2 region alone.
Lt Col Satish Kumar et al52  in their study on seroprevalence of human
parvovirus B19 in healthy blood donors by using very sensitive and specific
nested PCR revealed absence of parvovirus B19 DNA in  all donors found to
be tested positive for IgM antibodies alone or IgM and IgG antibodies together
or IgG antibodies alone.
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For safe transfusion of B19V negative blood to the high risk groups such
as pregnant women, patients with underlying haematological problems,
immunodeficient patients who are constantly multitransfused and transplant
recipients, either the blood units have to be IgM and PCR negative as a first
priority or else as a second priority, IgG positive blood units may be preferred
based on the above studies.
In our study, none of the samples were IgM positive and since IgG
positive samples most often revealed absence of viral DNA,16,33 PCR study was
not carried out to confirm B19V infection.
Since the window period of human parvovirus B19 infection is 10 to 14
days,16 which is relatively shorter, if absolutely essential, at least for high-risk
groups, PCR test to detect B19V DNA may be considered to rule out donors
with asymptomatic infections.
Socioeconomic status & B19V seroprevalence
In our study, about 29.4% (5 out of 17) of the donors in higher
socioeconomic group were found to be seropositive for Human parvovirus B19
infection while 33.9% (20 out of 59) in middle and 73.3% (22 out of 30) in
lower socio economic group were found to be seropositive for B19V infection.
This is in concordance with the study done by Kishore et al17 who reported that
the seropositivity increases in lower socio economic status when compared to
high socioeconomic group.
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Blood group
In our study, about 52.8% (19 out of 36) of the donors in “O” blood
group are found to be seropositive for Parvovirus B19, while 48.6% (18 out of
37) of the donors in “B” blood group, 33.3% (8 out of 16) in “A” blood group,
22.2% (2 out of 7) in “AB” blood group, 44.6% (45 out of 101) in Rh positive
and 40% (2 out of 5) in Rh negative are found to be seropositive. The
seroprevalence of parvovirus B19 is found to be higher in “O” blood group in
our study.
B19V infection and TTI
Since all donors included in our study were voluntary blood donors, the
prevalence of infections (HIV, HBV, HCV, Syphilis and Malaria) that are
screened for mandatory tests in the study group were low. Among 106 blood
donors one was found to be positive for HBsAg and two were positive for anti-
HCV. These three donors were positive for anti B19V IgG antibody. Nguyen L
Toan et al81 reported that 21.4% of HBV infected patients had parvovirus B19
co-infetion. Opaleye et al82 in their study reported that 18% of patients with a
HBV/HCV co-infection had Parvovirus B19 DNA.
Parvovirus B19 is considered as a major contaminant of blood and blood
products. Since the virus is resistant to different inactivation procedures, most
blood products that contain Parvovirus B19 DNA are considered to be
potentially infectious.56 Currently the Food and Drug Administration (FDA)
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guidelines and the European regulatory requirements  recommend testing
plasma pools by PCR and discard those with a Parvovirus B19 viral load of
>104 genome equivalent/ml.25
It is considered that the blood products containing virus titres below 104
IU/mL were not infectious. The significance of the neutralizing effect of anti-
B19 IgG has been considered in parvovirus B19 infection. The anti-B19 IgG in
the donated blood or recipients can neutralize the virus and prevent parvovirus
B19 infection. 11 U/ml of anti-B19 antibody can neutralize 4.3 log of
parvovirus B19 DNA.55 The safety of blood and plasma derivatives with regard
to parvovirus B19 has been a major concern to date.
Currently interventions for preventing parvovirus B19 transfusion from
blood components have not been implemented in the majority of developed
countries, because of the existing view that the blood components, with low
levels of B19 DNA will not transmit B19 infection.
Since it would be expensive to test all blood products for this emerging
pathogen, risk group approach in which only selected groups of patients are
given tested blood products. This ensures maximum safety to patients for
whom parvovirus B19 could cause problems.52 This method is similar to the
measures taken in blood transfusion medicine with respect to cytomegalovirus.
SUMMARY
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SUMMARY
In our study on seroprevalence of Human parvovirus B19 infection on
106 voluntary blood donors by using VP1 linear and VP2 conformational
antigen coated ELISA revealed.
? IgG seropositivity in 44.3% (47 out of 106) of donors.
? None of them were IgM positive.
? Percentage of IgG B19V seropositivity gradually increases along with
increase in age of the donors.(p=0.018).
? Since none of the samples were IgM positive, they were not subjected
for PCR study.
? Among 47 donors positive for IgG B19V, one was positive for HBsAg
and two were positive for anti-HCV.
? 50 out of 106 donors donated blood during late winter and spring season
of the year. Out of these 50 donors, 28 showed IgG B19V seropositivity,
which is relatively higher.(p=0.019).
? 22 out of 30 (73.3%) of the IgG B19V positive donors were from lower
socio-economic status. (p=0.001).
CONCLUSION
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CONCLUSION
In our study on seroprevalence of Human parvovirus B19 among
voluntary blood donors, 44.3% showed IgG positivity and none of them were
IgM positive. Since Human parvovirus B19 infection preferentially affects
erythroblasts in bone marrow, it is imperative to screen IgM B19V antibodies
before transfusion for at least high-risk groups.
For exclusion of donors with asymptomatic infections, advanced
techniques like PCR study to detect viral DNA shall be considered.
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DONOR INFORMATION SHEET
SEROPREVALENCE OF HUMAN PARVOVIRUS B19 AMONG
VOLUNTARY BLOOD DONORS IN CHENNAI
Human Parvovirus B19 is a common infection. Parvovirus B19 can be
transmitted through transfusion of blood and its blood products. It can cause
morbidity and mortality in certain high risk patients which could be prevented
by screening the blood products.
AIM
To study the seroprevalence of Human Parvovirus B19 among voluntary
blood donors.
PROCEDURE
Being a voluntary blood donor, you are recruited for this study. 5 ml of
blood will be taken separately from your donated blood and will be used for
detecting IgM and IgG antibodies by ELISA for Human Parvovirus B19.
BENEFITS AND RISKS
? All the investigations are done free of cost.
? There is no risk for these investigations.
CONFIDENTIALITY
Your privacy will be protected in so for as permitted by law. Only your
researcher and Ethical committee members will have access to the data
collected during the study.
PARTICIPATION
Your participation in this study is voluntary and you are free to decide
now or later whether to continue or discontinue from the study.
NAME OF THE DONOR:
SIGNATURE                   :
DATE                               :
Cµzu öPõøh¯õÍ¸UPõÚ uPÁÀ £iÁ®
 Cµzu öPõøh¯õÎPÎh® £õº÷Áõ øÁµì ¤19 (PARVOVIRUS
B19) öuõØÖ EÒÍuõ Gß£øu AÔ²® B´Ä.
SÔU÷PõÒ:
 Cµzu öPõøh¯õÎPÎh® £õº÷Áõ øÁµì ¤19 (PARVOVIRUS
B19) öuõØÖ Psk AÔuÀ.
ö\´¬øÓ:
 Cµzu öPõøh¯õÍ¶ß Cµzu ©õv¶°¼¸¢x 5 ª.¼ AÍÄ
Cµzu ©õv¶ GkUP¨£mk ÷©ØPsh £¶÷\õuøÚPÒ ELISA ¬øÓ°À
IgM, IgG Ab Bßi £õiPÒ AÍÄPÒ Psk¤iUP¨£k®.
£»ßPÐ® £õv¨¦PÐ®:
 AøÚzx £¶÷\õuøÚPÐ® C»Á\©õP ö\´¯¨£kQÓx. C¢u
£¶÷\õuøÚPÎÚõÀ GÆÂu £õv¨¦ªÀø».
CµP]¯¨ £õxPõ¨¦:
 \mh Áøµ¬øÓ°ß£i u[PÎß ö\õ¢u Âå¯[PÒ
£õxPõUP¨£k®. u[PÎß Bµõ´a]¯õÍº ©mk® C¢u
Bµõ´a]°ß÷£õx QøhUS® ¦ÒÎ Â£µ[PøÍ £¯ß£kzu C¯¾®.
£[PÎ¨¦:
 C¢u Bµõ´a]°À u[PÎß £[PÎ¨¦ ußÚõºÁ©õÚx. C¢u
Bµõ´a]°À u[PÎß £[PÎ¨£øÚz öuõhºÁuØS®,
Âk£kÁuØS® G¢u ÷{µ¬® u[PÐUS E¶ø©²sk.
Cµzu öPõøh¯õÍ¶ß ö£¯º :
øPö¯õ¨£®    :
÷uv      :
CONSENT
I confirm that I read and understood the information about the above
research study dated ______________ and I received chance to ask the
questions.
My participation in this study is voluntary and I know that I am free to
withdraw from the study at any time, without giving any reason and without
affecting any of my legal rights.
I agree to this access. I know that my identification will not be revealed
in any details that is released to third persons or published.
I agree not to restrict or interfere any data or results that are obtained
from this study.
I agree to participate in this research study for the above listed purpose.
Donor’s name                       :
Signature                              :                                                     Date    :
Signature of the person
who obtains consent            :                                                      Date    :
Donor ID Number               :


DONOR ID AGE INTERVAL GENDER WEIGHT IN KG AREA ZONE OCCUPATIONSOCIOECONOMIC CLASSTYPE OF DONORBLOOD GROUP Rh TYPE TTI MONTH IgM IgG
1578 4 1 69 MAGAPPAIR 7 2 3 1 3 1 NEGATIVE 7 2 2
1579 2 1 70 T.NAGAR 10 3 2 1 3 2 NEGATIVE 7 2 1
1580 2 1 90 ANNANAGAR 8 4 3 1 3 1 NEGATIVE 7 2 2
1581 2 1 65 T.NAGAR 10 3 2 1 1 1 NEGATIVE 7 2 2
1583 3 2 84 VALASARVAKKAM 11 1 1 1 1 1 NEGATIVE 7 2 2
1584 4 1 65 ASHOK NAGAR 10 1 2 1 3 1 NEGATIVE 7 2 1
1585 2 1 79 ASHOK NAGAR 10 4 2 1 3 2 NEGATIVE 8 2 1
1586 3 1 112 TIRUVANMAIYUR 13 3 2 1 2 1 NEGATIVE 8 2 1
1587 2 1 78 TIRUVANMAIYUR 13 3 2 1 3 1 NEGATIVE 8 2 1
1589 2 2 70 KOTTURPURAM 13 1 1 1 3 1 NEGATIVE 8 2 2
1592 3 1 95 MANDAVELI 13 3 2 1 2 1 NEGATIVE 8 2 1
1596 2 1 81 GUINDY 12 3 2 1 1 1 NEGATIVE 9 2 2
1632 2 1 74 KODAMBAKKAM 10 3 3 1 1 1 HBsAg(+) 9 2 1
1633 2 1 55 AVADI 7 1 2 1 4 1 NEGATIVE 9 2 2
1634 3 1 73 KORATUR 7 4 3 1 4 1 Anti-HCV (+) 9 2 1
1635 3 1 88 BESANT NAGAR 13 1 1 1 1 1 NEGATIVE 9 2 2
1636 3 1 77 MYLAPORE 10 1 2 1 3 1 NEGATIVE 9 2 1
1637 3 1 61 ANAKAPUTTUR OUTSIDE 3 2 1 3 1 NEGATIVE 9 2 2
1638 2 1 73 KORUKUPET 4 4 3 1 3 1 NEGATIVE 10 2 1
1639 3 1 78 PADI 8 3 2 1 3 1 NEGATIVE 10 2 1
1640 2 1 66 NUNGAMPAKKAM 10 2 2 1 4 1 NEGATIVE 10 2 2
1641 3 1 69 ANNANAGAR 8 3 2 1 2 1 NEGATIVE 10 2 1
1642 3 1 79 NUNGAMPAKKAM 10 1 1 1 1 1 NEGATIVE 11 2 2
1643 3 1 73 MAMBALAM 10 3 2 1 2 1 NEGATIVE 11 2 2
1644 3 1 80 KORATUR 7 3 2 1 2 1 NEGATIVE 11 2 2
1645 1 1 60 AMBATTUR 7 3 2 1 2 1 NEGATIVE 11 2 2
1647 2 1 57 PONNERI OUTSIDE 3 2 1 2 1 NEGATIVE 11 2 1
1648 2 1 76 MAMBALAM 10 3 2 1 2 1 Anti-HCV (+) 12 2 1
1649 2 1 60 ERNAVOOR 1 4 3 1 2 1 NEGATIVE 12 2 1
1650 4 1 100 NUNGAMPAKKAM 10 1 1 1 1 1 NEGATIVE 12 2 2
1651 3 1 85 VELACHERY 12 1 1 1 1 1 NEGATIVE 12 2 2
1653 3 1 69 T.NAGAR 10 1 1 1 2 1 NEGATIVE 12 2 2
3 3 1 70 ADAMPAKKAM 12 3 2 1 2 1 NEGATIVE 1 2 1
5 2 1 75 TEYNAMPET 9 3 3 1 1 1 NEGATIVE 1 2 1
6 2 1 70 PERAMBUR 6 2 3 1 1 1 NEGATIVE 1 2 1
MASTER CHART
7 2 1 85 PERAMBUR 6 2 2 1 3 1 NEGATIVE 1 2 1
8 3 1 74 MANALI 2 2 3 1 2 1 NEGATIVE 1 2 1
9 3 1 86 PERAMBUR 6 2 3 1 3 1 NEGATIVE 1 2 1
10 4 1 75 NAVALUR 7 3 3 1 3 1 NEGATIVE 1 2 1
11 2 1 66 ENNORE 1 2 3 1 3 1 NEGATIVE 1 2 2
12 2 1 58 ENNORE 1 2 2 1 2 1 NEGATIVE 1 2 1
14 2 1 62 AYANAVARAM 6 2 2 1 2 1 NEGATIVE 1 2 2
15 4 1 50 ENNORE 1 3 3 1 2 2 NEGATIVE 1 2 2
18 2 1 60 MOGAPPAIR 7 3 3 1 2 1 NEGATIVE 2 2 1
19 2 1 54 ORAGADAM 7 3 3 1 1 1 NEGATIVE 2 2 1
20 2 1 60 ORAGADAM 7 3 3 1 3 1 NEGATIVE 2 2 1
21 2 1 70 TAMBARAM 12 3 3 1 2 1 NEGATIVE 2 2 2
23 2 1 90 TAMBARAM 12 2 3 1 1 1 NEGATIVE 2 2 2
25 2 1 71 ANNANAGAR 8 3 3 1 1 1 NEGATIVE 2 2 1
26 3 1 79 VIRUKAMPAKKAM 11 3 3 1 2 1 NEGATIVE 2 2 1
27 2 1 63 ORAGADAM 7 3 3 1 2 1 NEGATIVE 2 2 1
28 3 1 70 ORAGADAM 7 3 3 1 3 1 NEGATIVE 2 2 1
31 2 1 57 ORAGADAM 7 3 3 1 3 1 NEGATIVE 2 2 1
38 2 1 76 SAIDAPET 13 2 1 1 3 1 NEGATIVE 2 2 2
37 5 2 50 CHROMPET 13 1 1 1 4 1 NEGATIVE 2 2 1
39 1 1 56 GUINDY 13 2 2 1 3 1 NEGATIVE 2 2 2
40 1 1 52 GUINDY 13 2 2 1 2 1 NEGATIVE 3 2 1
41 1 1 63 PERUNGUDI 14 2 2 1 1 1 NEGATIVE 3 2 2
42 2 1 78 AMBATTUR 7 2 2 1 2 1 NEGATIVE 3 2 1
43 1 1 50 PORUR 12 2 2 1 2 1 NEGATIVE 3 2 1
44 2 1 55 PORUR 12 1 1 1 2 1 NEGATIVE 3 2 2
45 1 1 65 CHROMPET 12 2 2 1 1 1 NEGATIVE 3 2 2
46 1 1 63 CHROMPET 12 2 2 1 3 1 NEGATIVE 3 2 2
47 1 1 75 TYNAMPET 9 2 2 1 3 1 NEGATIVE 3 2 1
48 1 1 65 MADHAVARAM 9 2 2 1 2 1 NEGATIVE 3 2 1
49 1 1 67 MADHAVARAM 3 2 2 1 3 1 NEGATIVE 3 2 1
50 1 1 75 MADHAVARAM 9 2 2 1 2 1 NEGATIVE 3 2 2
51 1 1 55 TONDAIARPET 4 2 2 1 1 1 NEGATIVE 3 2 2
53 1 1 65 ALANDUR 12 2 2 1 2 1 NEGATIVE 4 2 2
90 1 2 60 AYANAVARAM 6 2 2 1 1 1 NEGATIVE 4 2 2
112 2 1 112 GUINDY 13 1 1 1 3 1 NEGATIVE 4 2 1
113 4 1 68 AYANAVARAM 6 1 1 1 1 1 NEGATIVE 4 2 1
116 3 1 81 ADAYAR 13 1 1 1 3 1 NEGATIVE 4 2 2
117 2 1 69 ADAYAR 13 1 1 1 2 1 NEGATIVE 4 2 2
118 3 2 61 SEMBIAM 6 2 3 1 2 1 NEGATIVE 4 2 1
119 2 1 77 PERAMBUR 6 2 2 1 1 1 NEGATIVE 4 2 2
120 2 1 70 VILLIVAKKAM 6 2 2 1 3 1 NEGATIVE 4 2 2
122 2 1 70 VILLIVAKKAM 6 2 1 1 4 1 NEGATIVE 4 2 2
123 4 1 67 AYANAVARAM 6 2 1 1 3 1 NEGATIVE 4 2 1
124 1 1 60 AYANAVARAM 6 2 2 1 2 1 NEGATIVE 4 2 2
139 2 1 55 ROYAPURAM 5 2 2 1 2 1 NEGATIVE 4 2 2
140 2 1 62 MANALI 2 3 3 1 1 1 NEGATIVE 4 2 1
141 2 1 60 AMBATTUR 7 2 1 1 3 1 NEGATIVE 5 2 1
142 1 1 67 ANNANAGAR 8 2 2 1 3 1 NEGATIVE 5 2 2
143 2 1 65 NAVALLUR 15 2 2 1 2 1 NEGATIVE 5 2 2
144 2 1 55 NAVALLUR 15 3 3 1 2 1 NEGATIVE 5 2 1
145 2 1 50 NAVALLUR 15 2 2 1 3 1 NEGATIVE 5 2 2
146 2 1 54 NAVALLUR 15 3 3 1 2 1 NEGATIVE 5 2 2
147 2 1 52 KODAMBAKKAM 10 3 3 1 3 1 NEGATIVE 5 2 2
149 2 1 50 NAVALLUR 15 3 3 1 1 1 NEGATIVE 5 2 1
148 2 1 80 ANNANAGAR 8 3 3 1 3 1 NEGATIVE 5 2 1
180 2 2 55 TVK 6 2 2 1 1 1 NEGATIVE 5 2 2
181 2 2 60 MANALI 2 2 2 1 2 1 NEGATIVE 5 2 2
184 2 1 70 MANALI 2 2 2 1 3 1 NEGATIVE 5 2 2
185 1 1 62 ANNANAGAR 8 2 2 1 3 1 NEGATIVE 5 2 2
186 1 1 56 AMBATTUR 7 2 2 1 3 1 NEGATIVE 6 2 2
187 1 1 70 AMBATTUR 7 2 2 1 4 1 NEGATIVE 6 2 2
188 1 2 55 ANNANAGAR 8 2 2 1 4 1 NEGATIVE 6 2 2
189 1 1 78 PORUR 12 2 2 1 2 1 NEGATIVE 6 2 2
190 1 2 68 PORUR 12 2 2 1 4 1 NEGATIVE 6 2 2
192 1 1 63 VALASARVAKKAM 11 2 2 1 4 1 NEGATIVE 6 2 2
193 1 1 50 ADAMPAKKAM 12 2 2 1 2 1 NEGATIVE 6 2 2
194 1 1 65 ADAMPAKKAM 12 2 2 1 3 2 NEGATIVE 6 2 2
195 1 1 57 ALANDUR 12 2 2 1 1 2 NEGATIVE 6 2 2
196 1 1 57 ADAYAR 13 2 2 1 1 1 NEGATIVE 6 2 2
201 1 2 55 ADAMPAKKAM 12 2 2 1 2 1 NEGATIVE 6 2 2
Age group in
Years Code
18-20 1
21-30  2
31-40 3
41-50  4
>50 5
Gender Code
Male 1
Female 2
Occupation Code
Professional 1
Student 2
Clerical 3
Coolie 4
House wife 5
Socio economic
status Code
High 1
Middle 2
Low 3
Rh Typing Code
Positive 1
Negative 2
Month Code
January 1
February 2
March 3
April 4
May 5
June 6
July 7
August 8
September 9
October 10
November 11
December 12
Type of Donor Code
Voluntary 1
Replacement 2
Blood Group Code
A 1
B 2
O 3
AB 4
IgM Code
Positive 1
Negative 2
IgG Code
Positive 1
Negative 2
Zone Code
Thiruvotriyur 1
Manali 2
Madhavaram 3
Tondiarpet 4
Royapuram 5
Thiru-vi-ka Nagar 6
Ambattur 7
Anna Nagar 8
Teynampet 9
Kodambakkam 10
Valasaravakkam 11
Alandur 12
Adyar 13
Perungudi 14
Sozhanganallur 15

